What does matrix metalloproteinase-1 expression in patients with breast cancer really tell us?

BMC Medicine

Volumn 9, Issue , 2011, Pages

  Mannello, Ferdinando ^a  

^a UNIVERSITY OF URBINO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

INTERSTITIAL COLLAGENASE; MMP1 PROTEIN, HUMAN; TUMOR MARKER;

BREAST CANCER; BREAST TUMOR; CANCER CELL; CANCER GROWTH; CANCER SURVIVAL; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; HUMAN; NOTE; RETROSPECTIVE STUDY; STROMA CELL; TUMOR MICROENVIRONMENT; ARTICLE; BIOLOGICAL MODEL; BIOSYNTHESIS; FEMALE; GENE EXPRESSION; PATHOLOGY; PROGNOSIS; UNITED STATES;

BREAST NEOPLASMS; FEMALE; GENE EXPRESSION; HUMANS; MATRIX METALLOPROTEINASE 1; MODELS, BIOLOGICAL; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL; TUMOR MICROENVIRONMENT; UNITED STATES;

EID: 80051503653     PISSN: None     EISSN: 17417015     Source Type: Journal    
DOI: 10.1186/1741-7015-9-95     Document Type: Note

References (60)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011, 61:69-90. 10.3322/caac.20107, 21296855.
2. Sorlie T. Molecular portraits of breast cancer: tumour subtypes as distinct disease entities. Eur J Cancer 2004, 40:2667-2675. 10.1016/j.ejca.2004.08.021, 15571950.
3. Sorlie T. Introducing molecular subtyping of breast cancer into the clinic?. J Clin Oncol 2009, 27:1153-1154. 10.1200/JCO.2008.20.6276, 19204193.
4. Sorlie T. Molecular classification of breast tumors: toward improved diagnostics and treatments. Methods Mol Biol 2007, 360:91-114.
5. Borgan E, Sitter B, Lingjaerde OC, Johnsen H, Lundgren S, Bathen TF, Sorlie T, Borresen-Dale AL, Gribbestad IS. Merging transcriptomics and metabolomics--advances in breast cancer profiling. BMC Cancer 2010, 10:628. 10.1186/1471-2407-10-628, 2996395, 21080935.
6. Zhao X, Rodland EA, Sorlie T, Naume B, Langerod A, Frigessi A, Kristensen VN, Borresen-Dale AL, Lingjaerde OC. Combining gene signatures improves prediction of breast cancer survival. PLoS One 2011, 6:e17845. 10.1371/journal.pone.0017845, 3053398, 21423775.
7. Mannello F. Natural bio-drugs as matrix metalloproteinase inhibitors: new perspectives on the horizon?. Recent Pat Anticancer Drug Discov 2006, 1:91-103. 10.2174/157489206775246421, 18221029.
8. Mannello F, Luchetti F, Falcieri E, Papa S. Multiple roles of matrix metalloproteinases during apoptosis. Apoptosis 2005, 10:19-24. 10.1007/s10495-005-6058-7, 15711919.
9. Mannello F, Gazzanelli G. Tissue inhibitors of metalloproteinases and programmed cell death: conundrums, controversies and potential implications. Apoptosis 2001, 6:479-482. 10.1023/A:1012493808790, 11595838.
10. Tonti GA, Mannello F, Cacci E, Biagioni S. Neural stem cells at the crossroads: MMPs may tell the way. Int J Dev Biol 2009, 53:1-17. 10.1387/ijdb.082573gt, 19123122.
11. Hadler-Olsen E, Fadnes B, Sylte I, Uhlin-Hansen L, Winberg JO. Regulation of matrix metalloproteinase activity in health and disease. FEBS J 2011, 278:28-45. 10.1111/j.1742-4658.2010.07920.x, 21087458.
12. Mannello F, Tonti G, Papa S. Matrix metalloproteinase inhibitors as anticancer therapeutics. Curr Cancer Drug Targets 2005, 5:285-298. 10.2174/1568009054064615, 15975049.
13. Kessenbrock K, Plaks V, Werb Z. Matrix metalloproteinases: regulators of the tumor microenvironment. Cell 2010, 141:52-67. 10.1016/j.cell.2010.03.015, 2862057, 20371345.
14. Gialeli C, Theocharis AD, Karamanos NK. Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting. FEBS J 2011, 278:16-27. 10.1111/j.1742-4658.2010.07919.x, 21087457.
15. Cauwe B, Opdenakker G. Intracellular substrate cleavage: a novel dimension in the biochemistry, biology and pathology of matrix metalloproteinases. Crit Rev Biochem Mol Biol 2010, 45:351-423. 10.3109/10409238.2010.501783, 20812779.
16. Yan C, Boyd DD. Regulation of matrix metalloproteinase gene expression. J Cell Physiol 2007, 211:19-26. 10.1002/jcp.20948, 17167774.
17. Roy R, Yang J, Moses MA. Matrix metalloproteinases as novel biomarkers and potential therapeutic targets in human cancer. J Clin Oncol 2009, 27:5287-5297. 10.1200/JCO.2009.23.5556, 2773480, 19738110.
18. Delassus GS, Cho H, Hoang S, Eliceiri GL. Many new down- and up-regulatory signaling pathways, from known cancer progression suppressors to matrix metalloproteinases, differ widely in cells of various cancers. J Cell Physiol 2010, 224:549-558. 10.1002/jcp.22157, 20432456.
19. Gutierrez-Fernandez A, Fueyo A, Folgueras AR, Garabaya C, Pennington CJ, Pilgrim S, Edwards DR, Holliday DL, Jones JL, Span PN, Sweep FC, Puente XS, López-Otín C. Matrix metalloproteinase-8 functions as a metastasis suppressor through modulation of tumor cell adhesion and invasion. Cancer Res 2008, 68:2755-2763. 10.1158/0008-5472.CAN-07-5154, 18413742.
20. Lopez-Otin C, Palavalli LH, Samuels Y. Protective roles of matrix metalloproteinases: from mouse models to human cancer. Cell Cycle 2009, 8:3657-3662. 10.4161/cc.8.22.9956, 19844170.
21. McGowan PM, Duffy MJ. Matrix metalloproteinase expression and outcome in patients with breast cancer: analysis of a published database. Ann Oncol 2008, 19:1566-1572. 10.1093/annonc/mdn180, 18503039.
22. Eltarhouny SA, Elsawy WH, Radpour R, Hahn S, Holzgreve W, Zhong XY. Genes controlling spread of breast cancer to lung "gang of 4". Exp Oncol 2008, 30:91-95.
23. Eck SM, Blackburn JS, Schmucker AC, Burrage PS, Brinckerhoff CE. Matrix metalloproteinase and G protein coupled receptors: co-conspirators in the pathogenesis of autoimmune disease and cancer. J Autoimmun 2009, 33:214-221. 10.1016/j.jaut.2009.09.011, 2783549, 19800199.
24. Baker AH, Edwards DR, Murphy G. Metalloproteinase inhibitors: biological actions and therapeutic opportunities. J Cell Sci 2002, 115:3719-3727. 10.1242/jcs.00063, 12235282.
25. Kohrmann A, Kammerer U, Kapp M, Dietl J, Anacker J. Expression of matrix metalloproteinases (MMPs) in primary human breast cancer and breast cancer cell lines: New findings and review of the literature. BMC Cancer 2009, 9:188. 10.1186/1471-2407-9-188, 2706257, 19531263.
26. Boström P, Soderstrom M, Vahlberg T, Soderstrom KO, Roberts PJ, Carpen O, Hirsimaki P. MMP-1 expression has an independent prognostic value in breast cancer. BMC Cancer 2011,
27. Orimo A, Weinberg RA. Heterogeneity of stromal fibroblasts in tumors. Cancer Biol Ther 2007, 6:618-619.
28. Hasebe Y, Egawa K, Shibanuma M, Nose K. Induction of matrix metalloproteinase gene expression in an endothelial cell line by direct interaction with malignant cells. Cancer Sci 2007, 98:58-67. 10.1111/j.1349-7006.2006.00344.x, 17054435.
29. Gao MQ, Kim BG, Kang S, Choi YP, Park H, Kang KS, Cho NH. Stromal fibroblasts from the interface zone of human breast carcinomas induce an epithelial-mesenchymal transition-like state in breast cancer cells in vitro. J Cell Sci 2010, 123:3507-3514. 10.1242/jcs.072900, 20841377.
30. Hasebe T, Iwasaki M, kashi-Tanaka S, Hojo T, Shibata T, Sasajima Y, Kinoshita T, Tsuda H. Atypical tumor-stromal fibroblasts in invasive ductal carcinoma of the breast. Am J Surg Pathol 2011, 35:325-336.
31. Orimo A, Weinberg RA. Stromal fibroblasts in cancer: a novel tumor-promoting cell type. Cell Cycle 2006, 5:1597-1601. 10.4161/cc.5.15.3112, 16880743.
32. Eck SM, Cote AL, Winkelman WD, Brinckerhoff CE. CXCR4 and matrix metalloproteinase-1 are elevated in breast carcinoma-associated fibroblasts and in normal mammary fibroblasts exposed to factors secreted by breast cancer cells. Mol Cancer Res 2009, 7:1033-1044. 10.1158/1541-7786.MCR-09-0015, 2743167, 19584257.
33. Park YH, Jung HH, Ahn JS, Im YH. Ets-1 upregulates HER2-induced MMP-1 expression in breast cancer cells. Biochem Biophys Res Commun 2008, 377:389-394. 10.1016/j.bbrc.2008.09.135, 18851945.
34. Decock J, Hendrickx W, Vanleeuw U, V VB, Van HS, Christiaens MR, Ye S, Paridaens R. Plasma MMP1 and MMP8 expression in breast cancer: protective role of MMP8 against lymph node metastasis. BMC Cancer 2008, 8:77. 10.1186/1471-2407-8-77, 2278147, 18366705.
35. Eck SM, Hoopes PJ, Petrella BL, Coon CI, Brinckerhoff CE. Matrix metalloproteinase-1 promotes breast cancer angiogenesis and osteolysis in a novel in vivo model. Breast Cancer Res Treat 2009, 116:79-90. 10.1007/s10549-008-0085-3, 18597171.
36. Eguchi T, Kubota S, Kawata K, Mukudai Y, Uehara J, Ohgawara T, Ibaragi S, Sasaki A, Kuboki T, Takigawa M. Novel transcription-factor-like function of human matrix metalloproteinase 3 regulating the CTGF/CCN2 gene. Mol Cell Biol 2008, 28:2391-2413. 10.1128/MCB.01288-07, 2268440, 18172013.
37. Aldonyte R, Brantly M, Block E, Patel J, Zhang J. Nuclear localization of active matrix metalloproteinase-2 in cigarette smoke-exposed apoptotic endothelial cells. Exp Lung Res 2009, 35:59-75. 10.1080/01902140802406059, 19191105.
38. Polyak K, Kalluri R. The role of the microenvironment in mammary gland development and cancer. Cold Spring Harb Perspect Biol 2010, 2:a003244. 10.1101/cshperspect.a003244, 20591988.
39. Yan C, Boyd DD. Regulation of matrix metalloproteinase gene expression. J Cell Physiol 2007, 211:19-26. 10.1002/jcp.20948, 17167774.
40. DeCosse JJ, Gossens CL, Kuzma JF, Unsworth BR. Breast cancer: induction of differentiation by embryonic tissue. Science 1973, 181:1057-1058. 10.1126/science.181.4104.1057, 4269415.
41. Wallace JA, Li F, Leone G, Ostrowski MC. Pten in the breast tumor microenvironment: modeling tumor-stroma coevolution. Cancer Res 2011, 71:1203-1207. 10.1158/0008-5472.CAN-10-3263, 21303970.
42. Cichon MA, Degnim AC, Visscher DW, Radisky DC. Microenvironmental influences that drive progression from benign breast disease to invasive breast cancer. J Mammary Gland Biol Neoplasia 2010, 15:389-397. 10.1007/s10911-010-9195-8, 3011086, 21161341.
43. Allinen M, Beroukhim R, Cai L, Brennan C, Lahti-Domenici J, Huang H, Porter D, Hu M, Chin L, Richardson A, Schnitt S, Sellers WR, Polyak K. Molecular characterization of the tumor microenvironment in breast cancer. Cancer Cell 2004, 6:17-32. 10.1016/j.ccr.2004.06.010, 15261139.
44. Ma XJ, Dahiya S, Richardson E, Erlander M, Sgroi DC. Gene expression profiling of the tumor microenvironment during breast cancer progression. Breast Cancer Res 2009, 11:R7. 10.1186/bcr2222, 2687710, 19187537.
45. Brinckerhoff CE, Rutter JL, Benbow U. Interstitial collagenases as markers of tumor progression. Clin Cancer Res 2000, 6:4823-4830.
46. Polyak K. Molecular markers for the diagnosis and management of ductal carcinoma in situ. J Natl Cancer Inst Monogr 2010, 2010:210-213. 10.1093/jncimonographs/lgq019, 20956832.
47. Bissell MJ, Radisky D. Putting tumours in context. Nat Rev Cancer 2001, 1:46-54. 10.1038/35094059, 2975572, 11900251.
48. Stallings-Mann M, Radisky D. Matrix metalloproteinase-induced malignancy in mammary epithelial cells. Cells Tissues Organs 2007, 185:104-110. 10.1159/000101310, 17587815.
49. Radisky DC, Bissell MJ. Matrix metalloproteinase-induced genomic instability. Curr Opin Genet Dev 2006, 16:45-50. 10.1016/j.gde.2005.12.011, 2933219, 16377172.
50. Bissell MJ, Kenny PA, Radisky DC. Microenvironmental regulators of tissue structure and function also regulate tumor induction and progression: the role of extracellular matrix and its degrading enzymes. Cold Spring Harb Symp Quant Biol 2005, 70:343-356. 10.1101/sqb.2005.70.013, 3004779, 16869771.
51. Cheng S, Tada M, Hida Y, Asano T, Kuramae T, Takemoto N, Hamada J, Miyamoto M, Hirano S, Kondo S, Moriuchi T. High MMP-1 mRNA expression is a risk factor for disease-free and overall survivals in patients with invasive breast carcinoma. J Surg Res 2008, 146:104-109. 10.1016/j.jss.2007.05.032, 17663001.
52. Pearce EG, Laxton RC, Pereira AC, Ye S. Haplotype effects on matrix metalloproteinase-1 gene promoter activity in cancer cells. Mol Cancer Res 2007, 5:221-227. 10.1158/1541-7786.MCR-06-0139, 17339606.
53. Przybylowska K, Kluczna A, Zadrozny M, Krawczyk T, Kulig A, Rykala J, Kolacinska A, Morawiec Z, Drzewoski J, Blasiak J. Polymorphisms of the promoter regions of matrix metalloproteinases genes MMP-1 and MMP-9 in breast cancer. Breast Cancer Res Treat 2006, 95:65-72. 10.1007/s10549-005-9042-6, 16267613.
54. Przybylowska K, Zielinska J, Zadrozny M, Krawczyk T, Kulig A, Wozniak P, Rykala J, Kolacinska A, Morawiec Z, Drzewoski J, Blasiak J. An association between the matrix metalloproteinase 1 promoter gene polymorphism and lymphnode metastasis in breast cancer. J Exp Clin Cancer Res 2004, 23:121-125.
55. Mellick AS, Blackmore D, Weinstein SR, Griffiths LR. An assessment of MMP and TIMP gene expression in cell lines and stroma - tumour differences in microdissected breast cancer biopsies. Tumour Biol 2003, 24:258-270. 10.1159/000076140, 15001838.
56. Offit K, Robson ME. New pharmacogenomic paradigm in breast cancer treatment. J Clin Oncol 2010, 28:4665-4666. 10.1200/JCO.2010.31.2926, 20876427.
57. Chen ST, Pan TL, Juan HF, Chen TY, Lin YS, Huang CM. Breast tumor microenvironment: proteomics highlights the treatments targeting secretome. J Proteome Res 2008, 7:1379-1387. 10.1021/pr700745n, 3070414, 18290608.
58. Kenny PA, Bissell MJ. Tumor reversion: correction of malignant behavior by microenvironmental cues. Int J Cancer 2003, 107:688-695. 10.1002/ijc.11491, 2933180, 14566816.
59. Kenny PA, Lee GY, Bissell MJ. Targeting the tumor microenvironment. Front Biosci 2007, 12:3468-3474. 10.2741/2327, 2841020, 17485314.
60. Kenny PA, Nelson CM, Bissell MJ. The Ecology of Tumors: By perturbing the microenvironment, wounds and infection may be key to tumor development. Scientist 2006, 20:30. 2995893, 21132085.